Ratings Chlitina Holding Limited

Equities

4137

KYG211641017

End-of-day quote Taiwan S.E. Other stock markets 06:00:00 2024-06-04 pm EDT			5-day change	1st Jan Change
167 ^TWD	0.00%		-0.89%	-14.58%

May. 20	Chlitina Holding Limited Announces Directorate Changes to Weihu Health Management Consulting Co., Ltd	CI
May. 16	Chlitina Holding Limited announced that it has received TWD 468 million in funding	CI

Strengths

Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses

Revenue estimates are regularly revised downwards for the current and coming years.
For the last few months, analysts have been revising downwards their earnings forecast.
Over the past twelve months, analysts' consensus has been significantly revised downwards.
The group usually releases earnings worse than estimated.

Ratings chart - Surperformance

Sector: Personal Products

	1st Jan change	Capi.	Investor Rating	ESG Refinitiv
CHLITINA HOLDING LIMITED	-14.58%	410M		-
L'ORÉAL	+1.22%	265B		B-
GALDERMA GROUP AG	0.00%	19.15B	-	-
SHISEIDO COMPANY, LIMITED	+20.39%	13.17B		A-
COTY INC.	-16.71%	8.73B		A-
AMOREPACIFIC CORPORATION	+22.62%	7.95B		B+
PROYA COSMETICS CO.,LTD.	+12.17%	6.07B		B
NATURA &CO HOLDING S.A.	-8.70%	3.97B		B+
KOSÉ CORPORATION	-0.99%	3.89B		B
INTER PARFUMS, INC.	-16.66%	3.86B		C-

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes